Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mitoxantrone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 2/20 | 0.97 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | APEX1 | P27695 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | PIM1 | P11309 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mitoxantrone SCHEMBL29462659 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPK1TDP1LMNA | |
| Hydrochloric Acid SCHEMBL11305688 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPK1TDP1LMNA | |
| Mitoxantrone SCHEMBL29366412 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPK1TDP1LMNA | |
| Hydrochloric Acid SCHEMBL10522176 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPK1TDP1LMNA | |
| Mitoxantrone SCHEMBL1256885 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPK1TDP1LMNA | |
| Hydrochloric Acid SCHEMBL11039686 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPK1TDP1LMNA | |
| Mitoxantrone SCHEMBL532914 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPK1TDP1LMNA | |
| Mitoxantrone SCHEMBL3928 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPK1TDP1LMNA | |
| Mitoxantrone SCHEMBL2342900 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPK1TDP1LMNA | |
| Hydrochloric Acid SCHEMBL11278695 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPK1TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1861 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034101-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC INC (US) | 2026-02-05 | — | — | US | claimed |
| US-12383533-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | FROST BIOLOGIC, INC. (US) | 2025-08-12 | — | — | US | claimed |
| US-20240254220-A1 | COMBINED THERAPY USING ANTI-CD300C ANTIBODY | CentricsBio, Inc. (KR) | 2024-08-01 | — | — | US | claimed |
| EP-4339210-A1 | COMBINED THERAPY USING ANTI-CD300C ANTIBODY | CentricsBio, Inc. (KR) | 2024-03-20 | — | — | EP | claimed |
| US-20230248832-A1 | Small Molecule Ligand-Drug Conjugates for Targeted Cancer Therapy | UNIV EMORY (US) | 2023-08-10 | — | — | US | claimed |
| WO-2022240260-A1 | COMBINED THERAPY USING ANTI-CD300C ANTIBODY | 주식회사 센트릭스바이오 | 2022-11-17 | — | — | WO | claimed |
| US-20220008395-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC, INC. | 2022-01-13 | — | — | US | claimed |
| EP-3430031-B1 | PEPTIDES WITH ANTI-CANCER ACTIVITY | IDP DISCOVERY PHARMA S L (ES) | 2021-10-20 | — | — | EP | claimed |
| US-20210292755-A1 | NOVEL DOUBLE-STRANDED OLIGONUCLEOTIDES FOR THE TREATMENT OF CANCER | SELEXEL (FR) | 2021-09-23 | — | — | US | claimed |
| EP-3532086-A1 | NOVEL BISPECIFIC DOUBLE-STRANDED OLIGONUCLEOTIDE FOR TREATING CANCER | Selexel (FR) | 2019-09-04 | — | — | EP | claimed |
| CN-1939541-A | Immunostimulatory nucleic acids | UNIV IOWA RES FOUND (US) | 2007-04-04 | — | — | CN | claimed |
| US-20070041954-A1 | Compositions of placentally-derived stem cells for the treatment of cancer | MEDISTEM INC. | 2007-02-22 | — | — | US | claimed |
| WO-2007011693-A2 | COMPOSITIONS OF PLACENTALLY-DERIVED STEM CELLS FOR THE TREATMENT OF CANCER | MEDISTEM LABORATORIES, INC. (US) | 2007-01-25 | — | — | WO | claimed |
| EP-1728863-A2 | C-class oligonucleotide analogs with enhanced immunostimulatory potency | Coley Pharmaceutical GmbH (DE) | 2006-12-06 | — | — | EP | claimed |
| US-20060211639-A1 | Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer | PFIZER INC. | 2006-09-21 | — | — | US | claimed |
| US-20050009773-A1 | Using oligonucleotide immunostimulant mixture with drug | HYBRIDON, INC. | 2005-01-13 | — | — | US | claimed |
| EP-1296714-A2 | METHODS FOR ENHANCING ANTIBODY-INDUCED CELL LYSIS AND TREATING CANCER | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2003-04-02 | — | — | EP | claimed |
| US-20030026801-A1 | Methods for enhancing antibody-induced cell lysis and treating cancer | PFIZER INC. | 2003-02-06 | — | — | US | claimed |
| US-20020156033-A1 | Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer | COLEY PHARMACEUTICAL GROUP, INC. | 2002-10-24 | — | — | US | claimed |
| WO-2001097843-A2 | METHODS FOR ENHANCING ANTIBODY-INDUCED CELL LYSIS AND TREATING CANCER | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2001-12-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220008395-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | CCNA1, CCNE1, CCNB1 | TOP2A 612/4885MEN1 1042/4885KMT2A 1642/4885 |
| US-20260034101-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | NCOR1, NR0B1, NCOR2 | TOP2A 86/4885MEN1 3823/4885KMT2A 1913/4885 |
| US-20230248832-A1 | Small Molecule Ligand-Drug Conjugates for Targeted Cancer Therapy | SELL, EPCAM, SELPLG | TOP2A 560/4885MEN1 1311/4885KMT2A 782/4885 |
| US-12383533-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | CCNA1, CCNE1, CCNB1 | TOP2A 612/4885MEN1 1042/4885KMT2A 1642/4885 |
| US-20050009773-A1 | Using oligonucleotide immunostimulant mixture with drug | TLR3, TLR9, CD47 | TOP2A 55/4885MEN1 4009/4885KMT2A 3416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.